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Summary 1 
A rapid diagnostic work-up is required in patients with suspected heparin-induced 2 
thrombocytopenia (HIT). However, diagnosis of HIT is challenging due to a number of practical 3 
issues and methodological limitations. Many laboratory tests and a few clinical scoring systems 4 
are available but the individual characteristics and the diagnostic accuracy of these are hard to 5 
appraise. The 4Ts score is a well evaluated clinical assessment tool with the potential to rule-out 6 
HIT in many patients. Still, it requires Scoring tools such as the 4Ts are time-consuming, require 7 
experience and are is subject to a relevantn inter-observer variability. Immunoassays such as 8 
enzyme-linked immunosorbent assays or recently developed rapid assays are able to exclude HIT 9 
in a number of patients. But, a Accuracy of immunoassays differs depending on type of assay, 10 
threshold, antibody specificity and even manufacturer. Due to a comparatively low positive 11 
predictive value, HIT cannot be confirmed with by immunoassays alone. In addition, only some 12 
of them are immediately accessible, particularly in small laboratories.  While functional assays 13 
such as the serotonin release assay (SRA) and the heparin-induced platelet activation assay 14 
(HIPA) are considered a gold standard for diagnosis of HIT, they require a highly specialised 15 
laboratory. In addition,  and manysome of them are not adequately evaluated. In clinical practice, 16 
we recommend an integrated diagnostic approach combining not only clinical assessment (the 17 
4Ts score) but immunoassays and functional assays as well. We propose a clear diagnostic 18 
algorithm supporting clinical decision-making. Furthermore,  In this review, we provide an 19 
overview of all current laboratory techniques for HIT and discuss diagnostic pathways and 20 
strategies to reduce diagnostic errors, and future perspectives. 21 
Keywords: Heparin/adverse effects; Immunoassay/methods; Thrombocytopenia/chemically 22 
induced; Thrombocytopenia/diagnosis 23 
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 1 
Introduction 2 
Diagnostic work-up of patients with suspected heparin-induced thrombocytopenia (HIT) is 3 
hampered by major practical issues and a number of methodological limitations. OftenNot 4 
infrequently, suspicion is raised during night shifts and weekends when haematology consultants 5 
and elaborated laboratory services are not available. Thus, surgical registrars or intensive care 6 
unit consultants who are inexperienced with such patients may face major clinical decisions at 7 
times when there is little support. Most accurate diagnostic tests are functional assays, which are 8 
time-consuming, expensive and require a high level of laboratory expertise (1-3). Even in the 9 
best case scenario, results of these gold-standard tests will take at least two days and will only be 10 
available from Monday to Friday (4-6). However, the clinical decision regarding whether or not 11 
heparin should be stopped and treatment with an alternative anticoagulant started, must be made 12 
immediately within a few hours (7-10). Delaying this decision  may be life-threatening in 13 
patients with HIT (11), while treatment with alternative anticoagulants in non-HIT patients 14 
can be associated with major risks (12-14). Some clinical scoring systems and a number of 15 
immunoassays (Table 1) are currently available to help physicians select the most appropriate 16 
course of action. However, the diagnostic accuracy varies across these tests and all are associated 17 
with limitations (15). Given the large number of publications describing heterogeneous study 18 
designs and reporting imprecise and varying results, , it is hard to appraise the diagnostic 19 
characteristics of individual tests.  20 
With a focus on laboratory assays, wIn the present article, we will review the currently available 21 
diagnostic clinical and laboratory tests, summarise their diagnostic accuracy data and discuss 22 
practical issues. We will also elaborate on test variations and discuss strategies to reduce over-23 
diagnosis. 24 
Diagnostic pathways 25 
While estimating the value of diagnostic tests, it is helpful to appreciate the pathways in which 26 
they are used. Thus, we describe typical scenarios requiring a diagnosis of HIT that physicians 27 
may find themselves in, which will generally be informed by previous training and the technical 28 
infrastructure of the hospital. In virtually all situations, physicians must make an initial clinical 29 
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decision while awaitingwaiting for the results of the functional assay and the following scenarios 1 
may arise. First, the associated laboratory does not provide access to a rapid assay, no immediate 2 
access to a laboratory tests is available, neither a functional- assay nor an immuneimmuno-assay, 3 
because  (e.g. enzyme-linked immunosorbent assay [ELISA] is conducted , which is usually 4 
carried outonce or twice a week only). In this setting, thea initial decision is solely made on the 5 
basis of the estimated clinical probability using one of the validated scoring tools. The accuracy 6 
of the decision critically depends on the characteristics and appropriate execution of the clinical 7 
test. The decision may be revised when the immunoassay test result arrives several days later. 8 
However, most authors and recent guidelines recommend against conducting an immunoassay in 9 
patients with a low risk score (9, 16, 17). In the second scenario, an immunoassay is available 10 
Monday to Friday and a functional assay once a week. As above, physicians must decide on the 11 
outcome of the clinical tool but decisions can be revised quickly. This strategy puts equal weight 12 
on the clinical scoring system as well as laboratory test results. In the third case, ann 13 
immunoassay is conducted via a 24-hour service and the results of a functional assay will be 14 
reported at least once a week. In this preferable situation, physicians can consider clinical 15 
characteristics as well as results of immunoassays, and decisions will be modified accordingly 16 
corrected within a few days. However, in this scenario physicians may be tempted (tend?) to skip 17 
replace the fairly time-consuming task of gathering all information for clinical risk assessment 18 
with a laboratory test only (e.g. a rapid immunoassay), what places the patients at particular 19 
risks. filling a clinical assessment form and instead rely exclusively on the results from an 20 
immunoassay, which also have specific limitations. In all the above-mentioned scenarios, patient 21 
care can relevantly be improved with the help of the local haematology/couagulation consultancy 22 
service . As experienced in clinical, haematology consultation which may reducees the number 23 
of false-classified 4Ts scorings and improves interpretation of laboratory results. In addition, 24 
prophylactic treatment with fondaparinux can often be implemented in unclear cases 25 
Furthermore, it may save costs by reducing unnecessary testing and treatment with alternative 26 
anticoagulants. 27 
it is also possible to request and assessment of clinical probability and interpretation of 28 
laboratory results from the local haematology consultancy service. In clinical practice, many 29 
inappropriate decisions can be corrected this way, but it is a time-consuming and perhaps 30 
expensive intervention.  31 
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Assessing the pretest probability: clinical scoring tools 1 
As illustrated above, standardised assessment of the clinical probability of HIT is an essential 2 
step in the work-up of patients with suspected HIT. If conducted correctly, the probability of HIT 3 
can be estimated before determination of a laboratory test. Several clinical assessment tools have 4 
been developed, the outputs of which not only affect the interpretation of any laboratory test 5 
result but may in some instances represent the only diagnostic test to guide therapeutic decisions 6 
(see Figure 2 1).  7 
The 4Ts score 8 
The most extensively studied assessment tool, the 4Ts score, incorporates four typical clinical 9 
features of HIT: (i) thrombocytopenia, (ii) characteristic timing of thrombocytopenia, (iii) 10 
presence of thrombosis or other clinical sequelae, and (iv) the absence of other causes of 11 
thrombocytopenia, ((8), Table 1). The pretest probability is estimated to be low (0 to 3 points) , 12 
intermediate (4 or 5 points), or high with 6 to 8 points (18, 19). A number of evaluation studies 13 
assessed the diagnostic accuracy of the 4Ts score (18, 20-30) and a meta-analysis suggested a 14 
high negative predictive value (99.8%; 95% CI: 97-100%) (19). This result was not influenced 15 
by the type of performer (laboratory or treating physician), the prevalence, or the clinical setting 16 
as studied in sensitivity analyses. According to  this meta-analysisstudy, the probability of 17 
suffering from HIT can be estimated to be 0.82% in low risk 4Ts scoring, 13.414% (95% CI: 9 to 18 
22%) in intermediate scoring and 50.636% (95% CI: 40 to 82%)  in the high risk scoring. 19 
However, theThese results are clearly unsatisfactory for the purpose of ruling-inconfirming HIT.  20 
positive predictive value of an intermediate or even high 4Ts score was found to be 21 
unsatisfactory (14%; 95% CI: 9-22% and 64%; 95% CI: 40-82%, respectively). While the use of 22 
the 4Ts score as a screening test in the diagnostic pathways has been suggested, some 23 
methodological issues have been raised, in particular with regard to determination in clinical 24 
practice (31, 32). Most importantly, application of diagnostic accuracy measures to clinical 25 
practice was questioned because assessment of the 4Ts score was done by experts instead of 26 
referring physicians in most of the diagnostic accuracy studies (31). Indeed, a very recent, well-27 
designed prospective study considering these issues reported a much more limited diagnostic 28 
accuracysensitivity of the 4Ts score than estimated in the above mentioned meta-analysis 29 
(sensitivity 81.3%; 95% CI: 67.7, 94.8; specificity 63.8%; 95% CI: 59.6-68.0%) and a limited 30 
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agreement between physicians and expert observers (Cohens kappa 0.43; 95% CI, 0.29-0.57) 1 
(33). In clinical practice, we experienced several misdiagnosedses sed HIT cases due to low risk 2 
4Ts scorings and Figure 2 illustrates the dreadful course of a 30-year-old female patient who 3 
xxxxdied in the course of cerebral vein thrombosis. Thus, some authors conclude that a negative 4 
(<≤3) 4T’s score alone is insufficient to exclude HIT in clinical practice (24, 34).  5 
The HEP score 6 
The HIT expert probability (HEP) score is another clinical assessment tool which incorporates 7 
more clinical features than the 4Ts score (magnitude of platelet count fall, timing of platelet 8 
count fall, nadir platelet count, thrombosis, skin necrosis, acute systemic reaction, bleeding and 9 
other causes of thrombocytopenia) (29). Each of these features is evaluated using a score ranging 10 
from -3 (inconsistent with a HIT diagnosis) to +3 (consistent with a HIT diagnosis). Application 11 
of the HEP score resulted in a higher inter-observer agreement than the 4Ts score in one 12 
evaluation study (29). A cut-off value of 5 was associated with a positive predictive value of 13 
55% and a negative predictive value of 97%, showing operating characteristics similar to those 14 
observed with the 4Ts score. Nevertheless, the HEP score is more complex and may be more 15 
time consuming than the 4Ts. In addition, the number of evaluation studies is much more 16 
limited. 17 
Other scoring systems  18 
Another, simple score to exclude HIT has been suggested by Messmore et al (35). The system is 19 
designed to arrive at low (0) or possible (1) probability scores depending on the presence or 20 
absence of typical HIT manifestations without knowledge of laboratory test results (except 21 
platelet counts). In one evaluation study, it was able to exclude patients without HIT efficiently 22 
and it might be more useful for physicians who are not HIT experts. Lillo-Le Louët and 23 
colleagues developed a score to assess the probability of HIT in patients following 24 
cardiopulmonary bypass surgery (20). This score incorporates 3 variables that were predictive 25 
for HIT in a retrospective study (a biphasic platelet count profile, an interval of >5 days from 26 
CPB to the first day of suspected HIT and a CPB duration of >118 minutes). In an independent 27 
study, this score demonstrated a negative predictive value of 78%, suggesting that it may have 28 
inadequate sensitivity to be used as a clinical screening test (36). However, both the Mesmore 29 
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and Lillo-Le Louët scores require more validation in larger prospective studies before firm 1 
conclusions regarding their diagnostic accuracy can be drawn. 2 
Immunoassays 3 
Acquired thrombocytopenia is a frequent finding in hospitalised patients treated with heparin. 4 
Often, HIT is difficult to exclude or to confirm based on clinical information alone and 5 
physicians rely heavily on laboratory tests. Two classes of assays are available: functional 6 
(platelet activation) assays and (PF4-dependent) immunoassays. Immunoassays are pivotal in the 7 
diagnostic work-up of patients with suspected HIT and rely on detection of antibody binding by 8 
ELISA or particle-based immunoassays. However, diagnostic accuracy of immunoassays is quite 9 
variable. As an example, Figure 1 3 illustrates the difference of the probability of having HIT 10 
after a positive (or negative test respectively) between two available assays.  11 
Enzyme-linked immunosorbent assays (ELISAs)  12 
In ELISA, the target antigen (PF4/polyanion complexes) is bound to the solid phase, e.g. 13 
microtitre plate wells. Patient serum or plasma is added and an enzyme-labeled secondary 14 
antibody is used to detect the amount of anti-PF4/heparin antibodies bound in a semi-quantitative 15 
fashion. The intensity of the colour change, measured as optical density (OD), is proportional to 16 
the concentration of bound antibodies. The first polyspecific ELISA was developed by Amiral 17 
and Greinacher in 1992 (37, 38). Sensitivity was comparable to a heparin-induced platelet 18 
activation assay (HIPA) as evaluated in 209 patients with a clinical diagnosis of HIT (38). Since 19 
then, several in-house and commercially available assays have been developed and many studies 20 
have evaluated their performance characteristics (Table 1) (20, 21, 23, 24, 26-28, 39-63). A 21 
recent meta-analysis pooled this data and calculated the diagnostic accuracy according to 22 
different cut-off values: low threshold (OD ≤ 0.7, according to or slightly above the 23 
manufacturer’s instructions), intermediate threshold (OD 0.8 to 1.4) and high threshold (OD > 24 
1.4). Sensitivity of the polyspecific ELISA was excellent at low threshold (see Table 2) (64) (63) 25 
but relevant differences were observed with regard to different thresholds and particular 26 
manufacturers. However, specificity was limited for all assays (Table 2), restricting their value as 27 
a confirmatory test. With regard to ELISA, a significant inter-laboratory variation was observed 28 
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in a North American proficiency testing programme, in particular with regard to weak positive 1 
results (65). 2 
Following in vitro observations on the specificity of platelet-activating PF4/H-antibodies, IgG-3 
specific ELISAs were developed and tested in a number of studies (23, 41, 43, 45, 46, 48, 56, 66-4 
72). At low thresholds, sensitivity is again excellent (Table 2). However, even though several 5 
studies suggested a higher specificity than polyspecific assays (23), this observation was not 6 
generalizable in the above-mentioned meta-analysis (73). Data pooled from all available 7 
evaluation studies revealed a specificity of 85.4% for IgG-specific ELISAs (95% CI: 78.2-8 
90.6%), and 86.8% for polyspecific ELISAs (95% CI: 82.0-90.5%). While these ELISA assays 9 
can be excellent screening tests, they do have the major drawbacks of being time consuming and 10 
requiring a specialised laboratory.  11 
Particle-based immunoassays  12 
Several types of tests have been developed to overcome the drawbacks of ELISA assays: particle 13 
gel immunoassays (PaGIA), lateral flow immunoassays, chemiluminescent immunoassays 14 
[CLIA] and latex agglutination assays. PaGIA as well as lateral flow immunoassay can be 15 
implemented in routine laboratories, conducted 24-hours a day and technicians can perform these 16 
without specialised training. The polyspecific PaGIA is a particle agglutination assay uses the gel 17 
technique of ID-Micro typing with polymer particles coated with PF4/heparin complexes (52). It 18 
has been evaluated in a number of studies (21-24, 26, 33, 44, 45, 52, 54, 55, 71, 72, 74, 75). The 19 
sensitivity as well as the specificity of the PaGIA was excellent; the specificity was even higher 20 
than ELISA assays with low threshold (cutt-off according to manufacturer’s instructions; Table 21 
2, (73)). The principle of the lateral-flow immunoassay, which is a different particle-based 22 
immunoassay, is well known from modern pregnancy tests: labeled antibody complexes are 23 
retained and become visible during capillary action (71). The diagnostic characteristics have 24 
been evaluated in several studies (59, 69-72, 75, 76) from which the data have been pooled and a 25 
high sensitivity and reasonable specificity have been confirmed (Table 2; (73)). Nevertheless, 26 
PaGIA and lateral flow immunoassays share two disadvantages. First, the results are assessed 27 
visually (even though automatic applications exist), which permits variation in interpretation. 28 
Second, the results are expressed positively or negatively and titration studies are necessary to 29 
determine the anti-PF4/H antibody concentration (24). In addition, PaGIA is only available as a 30 
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polyspecific test. The particle immunofiltration assay is a different assay, but as yet has not been 1 
shown to demonstrate adequate diagnostic accuracy (73, 77). 2 
A desirable characteristic of tests to be implemented in modern laboratories is that they can be 3 
automated allowing them to be run 24 hours a day.  Two assays have been developed to meet 4 
this demand: the chemiluminescent immunoassay CLIA (polyspecific HemosIL® AcuStar HIT-5 
Ab and IgG-specific HemosIL® AcuStar HIT-IgG) and the latex agglutination assay 6 
(polyspecific HemosIL® HIT-Ab). Both assays can be used with the BIO-FLASH® analyzer 7 
(Inova Diagnostics, San Diego, CA, USA) or the ACL TOP coagulometers (Instrumentation 8 
Llaboratory, Bedford, MA, USA). Magnetic coated particles capture the PF4/heparin antibodies 9 
and in case of chemiluminescent immunoassayCLIA emitted light is measured (78). The 10 
diagnostic accuracy of these assays has been investigated in several large cohorts with 11 
favourable results (56, 58, 78-81). At low threshold, sensitivity was very high for both the 12 
polyspecific and the IgG-specific tests (Table 2) (73). Furthermore, a combination of a high 13 
sensitivity with a high specificity was estimated for the polyspecific assay (intermediate 14 
threshold) as well as IgG-specific assay (low threshold). Coated latex beads are used instead of 15 
magnetic particles with the polyspecific latex agglutination assay. In one evaluation study, 16 
sensitivity was found to be excellent, specificity was moderate (80)(Table 2).  17 
Diagnostic accuracy measures of rapid immunoassays have also been studied in another recent 18 
systematic review and meta-analysis comprising essentially the same primary studies cited above 19 
(82). A high sensitivity and specificity (corresponding to a high negative predictive value) was 20 
observed for some of the assays as well (PaGIA, lateral flow immunoassay and IgG-specific 21 
chemiluminescent immunoassayCLIA), suggesting their usefulness in diagnostic algorithms as 22 
mentioned below. In addition, implementation of rapid immunoassays is also supported by a 23 
study which modeled evaluated?the cost impact (83). 24 
Functional assays 25 
A subset of PF4/heparin-antibodies is able to activate platelets and cause clinical HIT under 26 
certain conditions (8, 84). The presence of platelet-activating antibodies can only be established 27 
using functional assays. In all tests, patient plasma or serum is incubated with donor platelets 28 
which can be prepared in one of two different ways: either as (a) washed platelets, or as (b) 29 
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platelet rich plasma (PRP) or whole blood (1). Washed platelet assays are considered preferable 1 
over other PRP or whole blood tests, because remaining plasma/serum may influence the 2 
antigen-antibody interaction as well as platelet activation (2, 8, 9, 85, 86). Table 3 summarizes 3 
the characteristics of the assays most often used. 4 
Washed platelet assays 5 
Both the serotonin release assay (SRA) and heparin induced platelet activation (HIPA) assay 6 
utilise washed platelets. Platelet activation is assessed by measurement of the release of 
14
C-7 
labeled serotonin from test platelets in SRA and or by visually determining the formation of 8 
platelet aggregates in HIPA (87, 88).  9 
In the HIPA assay, washed platelets from four healthy unselected donors are incubated with 10 
patient serum in the presence of buffer or heparin (0.2 IU/mL and 100 IU/mL). Incubation takes 11 
place in a round-bottom microtitre plate, with spinning magnetic spheres as a source of shear 12 
force. Platelet aggregate formation is determined visually at 5-minute intervals; the test is 13 
positive if aggregation is observed within 30 minutes (at 0.2 IU/mL but not at 100 IU/mL 14 
heparin) using platelet suspensions from at least two of the four donors. 15 
In the SRA, platelets obtained from a selected donor are pre-incubated with radioactive 14C-16 
serotonin. After washing, platelets are incubated with patient serum and heparin in flat-bottomed 17 
microtitre wells in duplicate on a plate shaker. After incubation for 60 minutes and 18 
centrifugation, supernatants of each reaction mixture are collected, and radioactivity is measured. 19 
Test results are expressed as percentage of serotonin release (compared to the 100% value 20 
obtained by detergent-induced platelet lysis). The test is considered positive if there is >20% 21 
release at low heparin concentrations (0.1 to 0.3 IU/mL) and <20% release at supratherapeutic 22 
heparin levels (100 IU/mL). However, a number of laboratories use a threshold of >50% 23 
serotonine release in order to increase specificity (89). 24 
The SRA was initially validated using a set of samples from patients with different degrees of 25 
clinical probability of HIT and a very large set of controls obtained from patients with a broad 26 
spectrum of clinical characteristics (87, 90). Not only high sensitivity and specificity were 27 
observed, but also a clear trend between clinical probability of HIT and the SRA results. These 28 
findings were confirmed in a prospective study following up all patients with heparin treatment 29 
based on strict clinical criteria (86). Equivalent diagnostic characteristics have been observed in 30 
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the evaluation of the HIPA test. Initially, Greinacher and co-workers studied sensitivity in 34 1 
samples, followed by sera from 209 patients (38, 88). Both functional assays are considered the 2 
"gold standard" for diagnosing HIT. However, these assays are difficult to perform, require 3 
selected healthy platelet donors and are restricted to few reference laboratories. Moreover, the 4 
SRA requires the use of the radioisotope, 14C-serotonin, which most laboratories try to avoid 5 
due to regulatory and safety issues. 6 
Even though SRA and HIPA are considered as gold standard for the diagnosis of HIT, some 7 
cases with incongruous results were observed, eg. positive tests in combination with negative 8 
immunoassays and an atypical clinical presentation (91). These rare cases were generally 9 
considered to be “false-positive” (91). In clinical practice, it is important not to always use any 10 
laboratory assay functional assays as the only test applied but to consider tin combination with 11 
appropriate assessment of the clinical presentations and immunoassay test results as well. 12 
Other washed platelet assays that either use ATP release detected by lumiaggregometry, platelet-13 
derived microparticle generation measured by flow cytometry, or proteolysis of FcγRIIa (the 14 
receptor through which HIT immune complexes activate platelets) assessed by 15 
chemiluminescence have been described, but still require independent validation. 16 
Whole blood assays 17 
Platelet-activating antibodies can be detected using the whole blood impedance analyser 18 
(Multiplate®, multiple electrode platelet aggregometry) in the presence of heparin. Blood from a 19 
selected donor is collected in hirudin-containing tubes. UFH is then added (0.5 or 100 IU/mL) 20 
and the suspension are incubated with patient citrated platelet-poor plasma (PPP) or heat-21 
inactivated serum. Changes in impedance are then recorded over a 15 minute period (92). In a 22 
multicentre Australian study, this assay, which does not require platelet preparation, 23 
demonstrated a sensitivity and specificity of 90.3% and 89.0%, respectively (81, 92). 24 
Other functional assays 25 
A number of other, less elaborate functional assays have been suggested; of these the heparin-26 
induced platelet aggregation test (PAT) and flow cytometry are the most often used. In PAT, 27 
platelet aggregometry is performed in the presence of two heparin concentrations using PRP of 28 
one to four, selected or unselected donors (85, 93). However, evaluation studies have revealed 29 
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varying results, partly explained by the modifications and selection of donors (38, 90, 93, 94). In 1 
general, sensitivity was clearly inferior to SRA/HIPA.  2 
Flow cytometry assays have been developed by a number of authors. Serum of patients and 3 
platelets from unselected donors are incubated with heparin and different measures of platelet 4 
activation are recorded (Annexin V (44, 95, 96), P-selectin (44, 95), and microparticles (97, 98)). 5 
Although these assays showed some agreement with the gold standard, standardisation and 6 
further evaluation studies are needed. 7 
Strategies to improve the specificity of immunoassays  8 
Several strategies have been developed and introduced to improve the specificity of 9 
immunoassays, increase their positive predictive value and limit the number of patients over 10 
treated.  11 
Determination of PF4/Heparin antibody titres 12 
A number of studies have observed that higher optical density values (in the case of ELISA type 13 
assays) are associated with an increased probability of having HIT (43, 99). Higher titres of 14 
antibodies have also been correlated with the likelihood of HIT in the case of PaGIA (24) and 15 
chemiluminescent immunoassayCLIA (58, 81). To confirm these observations, we pooled the 16 
data of all available evaluation studies in a recently conducted meta-analysis (64). The cutt-off 17 
values used in the primary studies were categorised into low, intermediate and high thresholds 18 
(corresponding to a low, intermediate, and high antibody titres). In line with previous 19 
observations, we found a remarkably increased specificity (or positive likelihood ratio) in all 20 
immunoassays (poly- and IgG-specific ELISA, PaGIA, poly- and IgG-specific chemiluminescent 21 
immunoassayCLIA) (73). However, the negative likelihood ratio increased as well, 22 
corresponding to a decline in sensitivity. In Table 2, we report a summary of the results that 23 
might help to define the best threshold. 24 
Application of IgG-specific assays 25 
In-vitro data suggest that IgG-specific antibodies account for the vast majority of HIT cases and 26 
several studies indeed observed an increased specificity of IgG-specific assays compared to 27 
polyspecific tests while sensitivity also remained high (23, 86, 100). We tried to confirm this 28 
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observation by pooling all available data in the above-mentioned meta-analysis. However, this 1 
could be replicated only in part (Table 2) (73). In addition, sensitivity was somewhat reduced, at 2 
least with intermediate and high cutt-off values. In clinical practice, we recommend selecting an 3 
appropriate combination of antibody specificity and threshold according to the respective 4 
likelihood ratios (eg. polypecific ELISA/ chemiluminescent immunoassay CLIA/ PaGIA with 5 
intermediate threshold or IgG-specific ELISA/ chemiluminescent immunoassayCLIA with a low 6 
threshold). 7 
Implementation of a high-dose heparin confirmation step 8 
It has been suggested that the specificity of HIT immunoassays could be improved by the 9 
implementation of a confirmatory step using supratherapeutic concentrations of heparin. This is 10 
because a persistently positive test despite high heparin concentrations can indicate an antibody 11 
that reacts against PF4, but not to the PF4/heparin complex. Such antibodies usually do not 12 
indicate HIT. While some studies support the use of this step, especially for weakly positive OD 13 
values <1.0 units, some of the clinically most relevant high-titre antibodies with strong platelet-14 
activating capacity are not inhibited (101). A recent meta-analysis however did not find this 15 
strategy helpful (64). Sensitivity was found to be low, at least in a subgroup of samples with a 16 
high titre of antibodies (73, 85). Because of this limitation and the corresponding difficulties in 17 
interpretation, we recommend against implementing this in routine clinical practice.  18 
Current challenges and future perspectives 19 
While the incidence of HIT in uncomplicated patients can be anticipated to decline due to the 20 
increasing use of low molecular weight heparins and alternative, non-heparin anticoagulants 21 
(102), HIT will remain a particular issue in specific patient populations, which have undergone 22 
cardiac surgery or are severely ill patients. Despite the progress in understanding the 23 
pathophysiology of HIT, there are still numerous diagnostic issues and treatment challenges. 24 
The clinical dilemma 25 
The management of patients with suspected HIT is associated with two major risks: missing 26 
patients with HIT and overtreatment. Physicians rely heavily on immunoassay test results and 27 
immunoassays are an essential part of most diagnostic pathways as discussed above. However, 28 
as few as 10-15% of sera test positive for anti-PF4/heparin antibodies and only up to 50% of 29 
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these contain clinically relevant, platelet-activating antibodies characteristic of HIT. Therefore, a 1 
considerable risk of “overdiagnosis” and subsequent mistreatment of patients without HIT exists 2 
(14). These patients are exposed to relevant risks. Therapy with alternative anticoagulants is 3 
associated with a high rate of bleeding complications (12), severe anaphylactic reactions (13), 4 
higher costs, and requires more management generally than compared to heparin treatment (12, 5 
14). Thus, an important aim of clinical practice and scientific inquiry is to develop and 6 
implement diagnostic tests and algorithms that reduce the number of false-positive results.  7 
On the other hand, increasing specificity should not be at the expense of test sensitivity, as 8 
missing a diagnosis of HIT is dangerous (64). The risk of severe thromboembolic complications, 9 
limb loss and even death is high in untreated HIT patients (11, 103). There is increasing 10 
awareness that a low risk 4Ts score does not exclude HIT in all cases (33, 34) and Figure 2 11 
illustrates a dreadful example. In addition, the sensitivity is below 95% in some immunoassays, 12 
suggesting that one in 20 HIT patients will be missed as well (64).  13 
Diagnostic algorithms 14 
In order to avoid the above-mentioned risks, the most important challenge in clinical practice is 15 
to estimate the probability of an individual patient having HIT. Our considerations above suggest 16 
that neither an immunoassay, nor a clinical assessment score alone is able to correctly diagnose 17 
HIT. However, combining different diagnostic approaches (clinical and laboratory) can improve 18 
diagnostic accuracy and may represent a strategy to solve this clinical dilemma (Figure 1).  19 
Diagnostic algorithms are the most obvious way of combining clinical and laboratory tests for 20 
the diagnosis of HIT (24, 33). In Figure 21, we illustrate a recently adapted diagnostic algorithm, 21 
(8). Assessing the clinical probability is suggested for all patients with suspected HIT. Given an 22 
appropriate application of the 4Ts score, HIT can be excluded in all most patients with a low risk 23 
scoring. However, conducting the 4Ts score correctly is difficult (31) and determination of an 24 
immunoassay is suggested in all cases where there are uncertainties (eg. unclear heparin 25 
exposure, missing platelet numbers).  26 
In contrast, HIT should be considered if an applied 4Ts score is high. In all other cases, 27 
determination of a quantitative immunoassay is recommended. However, the diagnostic accuracy 28 
varies between different assays and we recommend selecting a test with a high sensitivity as well 29 
as a high specificity (64). For example, we recommend choosing an intermediate threshold (cut-30 
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off value) in the case of polyspecific ELISA, PaGIA, as well as polyspecific chemiluminescent 1 
immunoassayCLIA. HIT can be essentially ruled-out if the immunoassay is negative or highly 2 
suspected if high titres of antibodies are demonstrated (eg. OD>=3.0). Even though HIT must be 3 
assumed in all other cases with a positive immunoassay, determination of a functional assay is 4 
recommended if possible. Depending on the individual setting, a functional assay will be 5 
conducted in more cases as well. 6 
There are nevertheless other ways of combining different diagnostic tests as well and all have the 7 
potential of reducing the number of false-positive and false-negative classifications. For 8 
example, a clinical scoring system and an immunoassay can be determined in parallel as 9 
suggested by several authors (2, 34, 104), and probabilities of clinical scoring systems and 10 
immunoassays can be combined with the use of likelihood ratios and Bayes’ theorem (24, 104, 11 
105). However, prospective studies evaluating these tools are still needed.  12 
Conclusion 13 
HIT is a life-threatening situation that requires an immediate diagnostic work-up. Not only 14 
missing a patient with HIT can result in catastrophic consequences, but overtreatment also 15 
carries a significant risk. The diagnostic work-up is, however, difficult due to a number of 16 
practical issues and limitations in the diagnostic accuracy of available assays.  The diagnostic 17 
pathway should be adjusted to the individual setting using well-defined diagnostic algorithms. 18 
The first step should include the assessment of the clinical probability according to a validated 19 
scoring system and laboratory investigations should additionally be performed if the probability 20 
is intermediate or high. An immunoassay with adequate sensitivity and specificity should be used 21 
to avoid over-treatment or failure to recognise HIT. Future efforts to address these challenges 22 
should focus on the improvement and clinical evaluation of diagnostic algorithms.  23 
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Tables 
Table 1: Available immunoassays for the diagnosis of HIT
 
(adapted from (73)) 












and high threshold* 
Requires specialised 
laboratory, determination in 
batches, daily determination 
rarely possible 
Genetic testing institute [GTI] Diagnostics, Waukesha, WI, USA (GTI-
PF4; HAT; PF4-Enhanced; GTI-IgG) 
Hyphen-BioMed, Neuville-Sur-Oise, France (Zymutest HIA IgGAM; 
Zymutest HIA IgG) 
Diagnostica Stago, Asnières-sur-Seine, France (Asserachrom HPIA) 
Gen-Probe-Waukesha, Waukesha, WI, USA (Gen-Probe PF4)
#
 
Technoclone GmbH, Vienna, Austria (Technozym) 
Particle gel 
immunoassay (PaGIA) 




Determination in standard 
laboratories possible, 24-hour 
service, observer-dependent 
Diamed, Cressier sur Morat, Switzerland (ID-H/PF4 PaGIA) 
Particle immunofiltration 
assay 
Polyspecific Visual assessment Observer-dependent Akers Biosciences Inc, Thorofare, NJ, USA (HealthTEST) 
Lateral flow 
immunoassay 
IgG specific Visual or automated 
assessment° 
Determination in standard 
laboratories possible, 24-hour 
service 
Diagnostica Stago, Asnières-sur-Seine, France (STic EXPERT HIT) 





Detection of emitted 
light 
Low, intermediate 
and high threshold† 
Automated determination 
possible, 24-hour service, 
expensive 
Instrumentation Laboratory, Bedford, MA, USA (HemosIL AcuStar HIT-
Ab; HemosIL AcuStar HIT-IgG) 
Latex agglutination 
assay 
Polyspecific Inhibition of 
agglutination 
Automatized determination 
possible, 24-hour service, 
expensive 
Instrumentation Laboratory, Bedford, MA, USA (HemosIL HIT-Ab) 
* low threshold: below or equal to OD 0.7, intermediate threshold: between OD 0.8 and 1.4, high threshold: above OD 1.4; ° positive/negative; † low threshold: below 1.0 U/ml, 
intermediate threshold: between 1.0 and 2.8 U/ml, high threshold: above 2.8 U/ml; 
#
 technically identical with GTI assay  
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Table 2: Diagnostic accuracy of immunoassays for diagnosis of HIT
+
 
Type of test Sensitivity Specificity Likelihood ratio 
 (percentages) Positive (95% CI) Negative (95% CI) 
Polyspecific ELISA     
Low threshold* 96.7 (89.7, 99.0) 86.8 (82.0, 90.5) 7.3 (5.4, 10.0) 0.04 (0.01, 0.12) 
Intermediate threshold* 98.4 (90.8, 99.7) 94.9 (90.5, 97.3) 19.3 (10.4, 36.0) 0.02 (0.00, 0.1) 
High threshold* 15.0 (14.5, 15.5) 100 (99.3, 100) 73.4 (28.2, 190.9) 0.3 (0.2, 0.5) 
IgG-specific ELISA     
Low threshold* 98.3  (95.1, 99.4) 85.4 (78.2, 90.6) 6.7 (4.5, 10.2) 0.02 (0.01, 0.05) 
Intermediate threshold* 91.2 (86.2, 94.5) 93.5 (89.1, 96.2) 14.1 (8.1, 24.5) 0.09 (0.05, 0.15) 
High threshold* 60.9 (59.7, 62.1) 99.4 (97.6, 100) 97.0 (53.0, 177.6) 0.4 (0.3, 0.5) 
PaGIA     
Low threshold° 96.5 (89.8, 98.9) 93.7 (83.1, 97.8) 15.3 (5.5, 42.3) 0.04 (0.01, 0.11) 
Intermediate threshold° 98.9 95.9 24.1 0.01 
Lateral flow immunoassay 98.4 (85.3, 99.9) 90.3 (84.4, 94.1) 10.1 (6.2, 16.5) 0.02 (0.00, 0.18) 
Particle immunofiltration assay 0.0 70.1 2.3 0.5 
Latex agglutination assay 100.0 75.6 3.7 0.0 
Polyspecific CLIchemiluminescent immunoassayA     
Low threshold† 98.9 (92.7, 99.8) 85.6 (79.3, 90.3) 6.9 (4.7, 10.0) 0.01 (0.00, 0.09) 
Intermediate threshold† 97.9 (94.6, 100.0) 93.1 (90.4, 95.8) 13.5 (9.5, 18.9) 0.0 (0.0, 0.1) 
High threshold† 98.3 (69.5, 99.9) 97.5 (94.4, 98.9) 39.5 (17.5, 89.2) 0.0 (0.0, 0.40) 
IgG-specific chemiluminescent immunoassayCLIA     
Low threshold† 98.8 (69.2, 100.0) 94.6 (90.7, 96.9) 18.3 (10.6, 31.5) 0.01 (0.00, 0.40) 
Intermediate threshold† 78.6 (75.9, 81.2) 98.7 (94.6, 100) 42.3 (20.1, 88.7) 0.2 (0.1, 0.3) 
High threshold† 74.2 (71.9, 76.5) 99.1 (95.4, 100) 47.8 (23.2, 98.7) 0.2 (0.1, 0.4) 
+
 According to results of a recent meta-analysis (73), please note differences between individual manufacturers; * low threshold: below or equal to OD 0.7, intermediate threshold: 
between OD 0.8 and 1.4, high threshold: above OD 1.4; ° low threshold: positive/negative, intermediate threshold: titer 2 to 3; † low threshold: below 1.0 U/ml, intermediate 
threshold: between 1.0 and 2.8 U/ml, high threshold: above 2.8 U/ml  
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Table 3: Commonly used functional assays for diagnosis of HIT 
Type of test Analytic principle Endpoint Platelets used Confirmation step Validation 
Serotonin release assay 
(SRA) 
Stimulation of platelet 
serotonin release by 
patient serum in the 
presence of heparin 





platelets from one selected 
donor 
Suppression with high-
dose heparin and inhibition 
using an Fc𝛾RIIA blocking 
antibody  
High agreement with 
clinical HIT (86, 87)  
Heparin-induced platelet 
activation assay (HIPA) 
Detection of platelet 
aggregation induced by 
patient serum in the 
presence of heparin 
Visual assessment of 
aggregation in microtitre 
plates 
Washed platelets from four 
unselected donors 
Suppression with high-
dose heparin and inhibition 
using an Fc𝛾RIIA blocking 
antibody 
High agreement with 
clinical HIT (38, 88) 
Heparin-induced platelet 
aggregation test (PAT) 
Activation of platelets 
(citrated PRP) in the 
presence of patient plasma 
and heparin 
Detection of aggregation 
by aggregometry 
PRP of one to four, 




Varying agreement with 
SRA, depending on  
platelet donor (94), lower 
sensitivity than SRA/HIPA 
with clinical criteria (38, 90, 
93) 
Flow cytometry Detection of markers for 




Increase of platelet 
activation markers of 
donor platelets in presence 
of heparin 
PRP of unselected donors None Some agreement with 
SRA (44, 95-98), requires 
standardisation and further 
evaluation 
Whole blood impedance 
aggregometry 
(Multiplate®) 
Activation of whole blood 
platelets in the presence of 
patient plasma and 
heparin 




Adequate agreement with 
SRA in two studies (81, 
106), requires confirmation 
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Figure legends 
Figure 1: Suggested diagnostic algorithm for diagnosis of HIT (adapted from (8)). The algorithm must be 
adapted according to the individual setting, taking the availability of laboratory tests such as functional assays 
into account. Of note, using this algorithm some HIT patients with a low risk 4Ts scoring will be missed, 
particularly in cases with inadequately determination of the 4Ts score. Thus, several authors suggested 
conducting an immunoassays in all patients with suspected HIT (24, 33, 34). However, this approach needs 
careful interpretation of immunoassay test results to avoid over-treatment. 
Figure 2: Diagnostic challenges in clinical practice. The 35-year-old female patient was admitted to hospital 
with fever and abdominal pain; the platelet count was 70x10
9
/L. She underwent uterine embolization and 
curettage 10 days earlier because of vaginal bleeding due to ectopic cervical pregnancy. HIT was rejected 
because of a low risk 4Ts scoring (3/8 points) and no immunoassay test was conducted (in accordance with 
recent guidelines). Patient suffered extensive intracranial haemorrhage three days later and cerebral venous 
thrombosis as well as HIT was diagnosed. Despite immediate start with lepirudin and intensive medical support, 
patient died on day 33. 
 Figure 13: Probability of having HIT with a particular immunoassay test result according to pre-test 
probability. The probability of having HIT is represented by the post-test probability on the Y-axis, the clinical 
probability (as measured by a clinical assessment tool) is illustrated by the pre-test probability on the X-axis. 
Two different immunoassays are shown with curves illustrative of the probability of HIT with a positive and 
negative immunoassay results as indicated. It is obvious that the probability of having HIT remains low in 
patients with a low clinical probability despite a positive immunoassay test result. In contrast, the probability of 
HIT is increasing in patients with a high clinical probability, even with a negative immunoassay test result 
(applies mainly to assays with a limited sensitivity).  
 
Figure 2: Suggested diagnostic algorithm for diagnosis of HIT (adapted from (8)). The algorithm must be 
adapted according to the individual setting, taking the availability of laboratory tests such as functional assays 
into account.(24, 33, 34) 
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